When and how should therapeutic phlebotomy be performed in polycythemia to maintain hematocrit below 45%?

Therapeutic Phlebotomy in Polycythemia Vera

All patients with polycythemia vera must undergo therapeutic phlebotomy to maintain hematocrit strictly below 45%, as this target significantly reduces cardiovascular death and major thrombosis by nearly 4-fold compared to higher targets. 1, 2

Target Hematocrit and Evidence Base

The hematocrit target of <45% is based on the landmark CYTO-PV randomized trial, which demonstrated that patients maintaining hematocrit <45% had only 2.7% cardiovascular events versus 9.8% in those with hematocrit 45-50% (hazard ratio 3.91) 1, 2. This represents Category 1 evidence and forms the cornerstone of all major guideline recommendations 1, 3.

Important caveat: Consider individualizing to 42% for female patients or those with progressive symptoms, though the primary target remains <45% 3.

Phlebotomy Protocol

Induction Phase

• Volume: Remove 300-450 mL per session 1
• Frequency: Weekly or twice weekly until target hematocrit achieved 1
• A fixed protocol of 350 mL every 3 days has shown rapid improvement with minimal adverse events 4

Maintenance Phase

• Volume: Same as induction (300-450 mL per session) 1
• Frequency: Determined by hematocrit monitoring—perform phlebotomy whenever hematocrit rises above 45%
• Monitor every 3-6 months or more frequently if clinically indicated 3

When Phlebotomy Alone Is Insufficient

Critical warning: Requiring ≥3 phlebotomies per year during maintenance identifies patients with increased disease proliferation and 3.3-fold higher thrombosis risk (20.5% vs 5.3% at 3 years) 5. This mandates consideration of cytoreductive therapy.

Indications to Add Cytoreductive Therapy Beyond Phlebotomy:

Mandatory indications:

• Age ≥60 years or prior thrombosis (high-risk disease) 1, 3

Additional indications in any patient:

• Poor tolerance to phlebotomy 1
• Frequent/persistent phlebotomy need (≥3 per year) 1, 5
• Symptomatic or progressive splenomegaly 1, 3
• Platelet count >1500 × 10⁹/L 1
• Leukocyte count >15 × 10⁹/L 1
• Progressive disease-related symptoms (pruritus, night sweats, fatigue) 1, 3

Monitoring Strategy

• Baseline: Complete blood count before each phlebotomy 4
• Interval: Assess for thrombosis, bleeding, and disease progression every 3-6 months 3
• Iron studies: Monitor at enrollment and after achieving target hematocrit, as phlebotomy induces iron deficiency 4, 6

Iron Deficiency Management

Iron deficiency is expected and therapeutic with phlebotomy. Only supplement iron if severe tissue iron deficiency causes detrimental symptoms (pica, mouth paresthesia, esophagitis, restless legs) 1. If iron supplementation worsens hematocrit control, this mandates cytoreductive therapy 1.

Real-World Outcomes

Despite guideline recommendations, real-world data shows poor hematocrit control: only 36-44% of patients on phlebotomy alone maintain hematocrit <45% at 6-12 months 7, and 67.8% of patients remain above target after 1 year 8. This underscores the importance of aggressive monitoring and low threshold for adding cytoreduction.

Adjunctive Therapy

All patients require:

• Low-dose aspirin 81-100 mg daily (unless contraindicated) 1, 3, 9
• Aggressive cardiovascular risk factor management 1, 3